HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-00449-z |
Summary: | Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy. |
---|---|
ISSN: | 2041-1723 |